Novartis Still Faces Suit Over Macular Degeneration Treatment

Novartis Pharmaceuticals Corp. must keep defending a man’s suit alleging a macular degeneration treatment caused blindness, following a Florida federal court’s ruling that federal drug labeling law doesn’t bar the claims.

Kenneth Davison received three injections of the biologic product Beovu between January 2020 and April 2020. He alleged the treatment damaged his retinal vein system, leaving him blind in his left eye.

There were no warnings regarding these risks when he was treated, Davison said. In June 2020, however, Beovu’s product labeling was updated to include warnings about the specific injuries he sustained.

Davison alleged that the warnings were ...